New Results for GIVLAARI® (givosiran) at the Thrombosis & Hemostasis Summit of North America 2020 Virtual Conference

New Results for GIVLAARI® (givosiran) at the Thrombosis & Hemostasis Summit of North America 2020 Virtual Conference

During the Thrombosis & Hemostasis Summit of North America 2020 Virtual Conference, we presented new data from a post-hoc analysis of the ENVISION Phase 3 study of GIVLAARI® (givosiran), evaluating hemin use in patients with acute hepatic porphyria. We also presented encore data evaluating healthcare resource utilization among patients with acute intermittent porphyria.

Kuter, et al. “Hemin Use in Patients with Acute Hepatic Porphyria Treated with Givosiran: A Post Hoc Analysis of the Phase 3 ENVISION Study”

Silver, et al. “Disease Burden and Healthcare Utilization Among Patients with Acute Intermittent Porphyria Experiencing Chronic Pain: Analyses from a National Healthcare Database”



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.